Template:HSV-1 antiviral treatment: Difference between revisions

(Convert to AntibioticDose templates for SMW integration)
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
===Anti-viral Treatment===
===Anti-viral Treatment===
''Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible''
====Normal Host====
 
'''Normal Host'''
*Options:
*Options:
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days
**[[Acyclovir]]
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref>
***{{AntibioticDose|drug=Acyclovir|dose=400 mg PO 5x/day (q4hrs while awake) x 5 days|context=Normal host|population=Adult}} OR
**[[Valacyclovir]] (significantly higher bioavailability than acyclovir)
***{{AntibioticDose|drug=Acyclovir|dose=40-80mg/kg PO divided in 3-4 doses for 5-7 days|context=Normal host|population=Pediatric}} OR
**[[Famciclovir]]
***Can also be used as topical cream 5x per day
**{{AntibioticDose|drug=Famciclovir|dose=500mg PO BID x 7 days|context=Normal host|population=Adult}} OR
**{{AntibioticDose|drug=Valacyclovir|dose=2g PO q12h x 1 day|context=Normal host|population=Adult}}


'''Immunocompromised'''
====Immunocompromised====
*Options:
*Options:
**[[Acyclovir]]  
**[[Acyclovir]]
***5 mg/kg IV (over 1 hours) q8h x 7 days, OR
***{{AntibioticDose|drug=Acyclovir|dose=5 mg/kg IV q8h x 7 days|context=Immunocompromised|population=Adult}} OR
***400mg PO 5x/day x 14-21 days
***{{AntibioticDose|drug=Acyclovir|dose=400mg PO 5x/day x 14-21 days|context=Immunocompromised (oral)|population=Adult}}
**[[Famciclovir]] 500mg PO BID x 7 days, OR
**{{AntibioticDose|drug=Famciclovir|dose=500mg PO BID x 7 days|context=Immunocompromised|population=Adult}} OR
**[[Valacyclovir]] 500mg PO BID x 5-10 days
**{{AntibioticDose|drug=Valacyclovir|dose=500mg PO BID x 5-10 days|context=Immunocompromised|population=Adult}}

Latest revision as of 22:28, 20 March 2026

Anti-viral Treatment

Normal Host

  • Options:

Immunocompromised